You need to enable JavaScript to run this app.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated
Cookie Policy
Yes, I accept cookies
Steering Committee
About Us
Newsletter
Contact
Visit:
Steering Committee
About Us
Newsletter
Contact
Types
Therapeutics
Congresses
Trials
Expert Opinions
ASH 2020
AML Types
Signaling pathway mutations
Epigenetic modifier mutations
Origin
Chromosomal aberrations
Nucleophosmin mutations
Tumor suppressor mutations
Spliceosome mutations
Transcription factor mutations
Cohesin mutations
View all Types
Christopher Hourigan
Christopher Hourigan
Types
CBFB-MYH11
Core binding factor
NPM1
Interventions
Allo-HSCT
Chemotherapy
Idarubicin
Lenalidomide
Events
EHA 2018
EHA 2019
MRD Symposium
SOHO 2019
Trials
FLUGAZA
HO132
NCT01339910
All
|
2 Articles
|
1 Video
|
0 Podcasts